Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A.
Sigal
N H
NH
Department of Immunology Research, Merck, Sharp & Dohme Research Laboratories, Rahway, New Jersey.
Lin
C S
CS
Siekierka
J J
JJ
D000900:Anti-Bacterial Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D000935:Antifungal Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D018106:CD28 Antigens; D002478:Cells, Cultured; D003524:Cyclosporins / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis; D015759:Ionomycin / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects*; D011090:Polyenes / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D020123:Sirolimus; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D016559:Tacrolimus; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D000935:Antifungal Agents; D000945:Antigens, Differentiation, T-Lymphocyte; D018106:CD28 Antigens; D003524:Cyclosporins; D007376:Interleukin-2; D011090:Polyenes; D012333:RNA, Messenger; D015759:Ionomycin; D013755:Tetradecanoylphorbol Acetate; D020123:Sirolimus; D016559:Tacrolimus